Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for Which the HIV Reservoir is Low to Moderate

Trial Profile

Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for Which the HIV Reservoir is Low to Moderate

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Integrase inhibitors; Maraviroc; Non-nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms TRULIGHT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Aug 2018.
    • 02 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top